|
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations |
|
|
|
Title: |
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations |
Author: |
Deschamps, Romain Papeix, Caroline Ayrignac, Xavier Bourre, Bertrand Ciron, Jonathan Cohen, Mikael Collongues, Nicolas Deiva, Kumaran Durand Dubief, Françoise Laplaud, David-Axel Maillart, Elisabeth Michel, Laure Pique, Julie Ruet, Aurélie Thouvenot, Eric Zéphir, Hélène Marignier, Romain Audoin, Bertrand |
Appeared in: |
Revue neurologique |
Paging: |
Volume 180 () nr. 8 pages 711-714 |
Year: |
2024 |
Contents: |
|
Publisher: |
Elsevier Masson SAS |
Source file: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|